EP3687537A4 - Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple - Google Patents
Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple Download PDFInfo
- Publication number
- EP3687537A4 EP3687537A4 EP18862773.1A EP18862773A EP3687537A4 EP 3687537 A4 EP3687537 A4 EP 3687537A4 EP 18862773 A EP18862773 A EP 18862773A EP 3687537 A4 EP3687537 A4 EP 3687537A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- new
- multiple myeloma
- usp7 inhibitors
- usp7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563375P | 2017-09-26 | 2017-09-26 | |
| PCT/US2018/052797 WO2019067503A1 (fr) | 2017-09-26 | 2018-09-26 | Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3687537A1 EP3687537A1 (fr) | 2020-08-05 |
| EP3687537A4 true EP3687537A4 (fr) | 2021-06-16 |
Family
ID=65903565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18862773.1A Pending EP3687537A4 (fr) | 2017-09-26 | 2018-09-26 | Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11465983B2 (fr) |
| EP (1) | EP3687537A4 (fr) |
| JP (3) | JP7402792B2 (fr) |
| AU (1) | AU2018342089B2 (fr) |
| CA (1) | CA3072353A1 (fr) |
| WO (1) | WO2019067503A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3072353A1 (fr) | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Nouveaux inhibiteurs d'usp7 pour le traitement du myelome multiple |
| JP7508449B2 (ja) * | 2018-10-22 | 2024-07-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ７の阻害 |
| MX2021006542A (es) * | 2018-12-06 | 2021-07-07 | Almac Discovery Ltd | Inhibidores de la usp19 para usarse en terapia. |
| EP3965749A4 (fr) * | 2019-05-06 | 2023-06-21 | Valo Health, Inc. | Inhibition de l'usp19 |
| EP4110393A1 (fr) | 2020-02-28 | 2023-01-04 | Immunologik GmbH | Inhibiteurs de désubiquitinases humaines pour le traitement d'infections coronavirales |
| CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999053924A1 (fr) * | 1998-04-17 | 1999-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent analgesique |
| WO2007147217A1 (fr) * | 2006-06-22 | 2007-12-27 | Prana Biotechnology Limited | Procédé de traitement d'une tumeur cérébrale gliome |
| EP2565186A1 (fr) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| WO2016126926A1 (fr) * | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60326436D1 (en) | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| EP3253765A1 (fr) * | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thiénopyrimidinones utilisées comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| US9938300B2 (en) * | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| GB201612938D0 (en) | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CA3072353A1 (fr) | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Nouveaux inhibiteurs d'usp7 pour le traitement du myelome multiple |
| JP7508449B2 (ja) | 2018-10-22 | 2024-07-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ７の阻害 |
-
2018
- 2018-09-26 CA CA3072353A patent/CA3072353A1/fr active Pending
- 2018-09-26 WO PCT/US2018/052797 patent/WO2019067503A1/fr not_active Ceased
- 2018-09-26 JP JP2020515000A patent/JP7402792B2/ja active Active
- 2018-09-26 AU AU2018342089A patent/AU2018342089B2/en active Active
- 2018-09-26 US US16/650,727 patent/US11465983B2/en active Active
- 2018-09-26 EP EP18862773.1A patent/EP3687537A4/fr active Pending
-
2022
- 2022-09-02 US US17/902,512 patent/US20230265070A1/en active Pending
-
2023
- 2023-09-01 JP JP2023142246A patent/JP2023164918A/ja active Pending
-
2025
- 2025-12-05 JP JP2025235397A patent/JP2026031721A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999053924A1 (fr) * | 1998-04-17 | 1999-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent analgesique |
| WO2007147217A1 (fr) * | 2006-06-22 | 2007-12-27 | Prana Biotechnology Limited | Procédé de traitement d'une tumeur cérébrale gliome |
| EP2565186A1 (fr) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| WO2013030218A1 (fr) * | 2011-09-02 | 2013-03-07 | Hybrigenics Sa | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique à l'ubiquitine |
| WO2016126926A1 (fr) * | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
Non-Patent Citations (1)
| Title |
|---|
| LAMBERTO ILARIA ET AL: "Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7", CELL CHEMICAL BIOLOGY, vol. 24, no. 12, 21 December 2017 (2017-12-21), pages 1490, XP085326765, ISSN: 2451-9456, DOI: 10.1016/J.CHEMBIOL.2017.09.003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3072353A1 (fr) | 2019-04-04 |
| JP7402792B2 (ja) | 2023-12-21 |
| JP2026031721A (ja) | 2026-02-24 |
| AU2018342089A1 (en) | 2020-02-27 |
| JP2023164918A (ja) | 2023-11-14 |
| EP3687537A1 (fr) | 2020-08-05 |
| AU2018342089B2 (en) | 2024-07-11 |
| US11465983B2 (en) | 2022-10-11 |
| US20230265070A1 (en) | 2023-08-24 |
| WO2019067503A1 (fr) | 2019-04-04 |
| US20200347031A1 (en) | 2020-11-05 |
| JP2020535124A (ja) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3687537A4 (fr) | Nouveaux inhibiteurs d'usp7 pour le traitement du myélome multiple | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3432927A4 (fr) | Inhibiteurs trispécifiques pour le traitement du cancer | |
| EP3397963A4 (fr) | Inhibition de mapk p38 pour le traitement du cancer | |
| EP3641829A4 (fr) | Promédicament d'interféron pour le traitement du cancer | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| EP3526328A4 (fr) | Polythérapie pour l'inhibition de c3 | |
| EP3558313A4 (fr) | Substances pour le traitement d'affections liées à la stéatose hépatique | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3267995A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3897626C0 (fr) | Tinostamustine pour le traitement du myélome multiple | |
| EP3630080A4 (fr) | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| EP3947460A4 (fr) | Agents multispécifiques pour le traitement du cancer | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3430400A4 (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| EP3716966A4 (fr) | Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie | |
| EP3870179A4 (fr) | Inhibition d'usp7 | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| EP3478284A4 (fr) | Composés et compositions pour le traitement du cancer | |
| EP4021858A4 (fr) | Traitement d'azoles | |
| EP3344650A4 (fr) | Aav-epo pour le traitement d'animaux de compagnie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200430 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 401/06 20060101ALI20210223BHEP Ipc: C07D 403/06 20060101ALI20210223BHEP Ipc: A61K 31/44 20060101ALI20210223BHEP Ipc: A61K 31/4436 20060101ALI20210223BHEP Ipc: C07D 401/14 20060101AFI20210223BHEP Ipc: A61K 31/4439 20060101ALI20210223BHEP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031440000 Ipc: C07D0401140000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20210519 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 401/14 20060101AFI20210512BHEP Ipc: C07D 403/06 20060101ALI20210512BHEP Ipc: C07D 401/06 20060101ALI20210512BHEP Ipc: A61K 31/44 20060101ALI20210512BHEP Ipc: A61K 31/4436 20060101ALI20210512BHEP Ipc: A61K 31/4439 20060101ALI20210512BHEP |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |